LOS ANGELES, Feb. 28, 2012 /PRNewswire/ -- The Bureau of Educational and Cultural Affairs of the U.S.

IRIS INTERNATIONAL, INC. (NASDAQ: IRIS), after extensive consultation with the US Food and Drug Administration (FDA), intends to resubmit its 510(k) for its NADiA(TM) PSA (Prostate Specific Antigen) ultra-sensitive diagnostic test with a prognostic claim.